N/A N=75 Diagnostic

Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease

Gastro-esophageal Reflux Disease

Bottom Line

View on ClinicalTrials.gov: NCT02114216 ↗

Enrolled (actual)

Serious AEs

—

Results posted

May 2016

Primary outcome: Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: endoscopic mucosal biopsy (Procedure)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Seoul National University Bundang Hospital
Primary completion: Aug 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa	1.14; 3.25; 2.33; 1.39; 2.47; 2.05	—
SECONDARY PAR2 and IL-8 Expression of Esophageal Mucosa	1.37; 2.42; 2.29; 2.01; 4.36; 4.01	—

Summary

Transient receptor potential vanilloid-1 (TRPV1) receptor and proteinase-activated receptor 2 (PAR2) have been implicated in the mechanism of acid induced inflammation in gastroesophageal reflux disease (GERD). We aimed to evaluate TRPV1 and PAR2 mRNA expression levels in the GERD patients and their relationship with endoscopic findings and reflux symptoms.

Eligibility Criteria

Inclusion Criteria

subjects who completed upper GI endoscopy and questionnaires about GERD symptoms

Exclusion Criteria

a history of gastrointestinal surgery
Barrett's esophagus
esophageal motility disorder
duodenal ulcer
benign gastric ulcer
gastroduodenal cancer
if he or she had any history of systemic disease requiring chronic medication (except for hypertension and diabetes mellitus).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02114216). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.